Sustained Ketamine Effectiveness for Suicidal Ideation (SKESI)

This observational cohort study (n=128) will evaluate the sustained effectiveness of intravenous (IV) ketamine for suicidal ideation in adults experiencing a suicidal crisis due to major depressive disorder.

Conducted at the University Hospital, Montpellier, this retrospective study analyses medical records of patients treated with IV ketamine in the Psychiatric Emergency and Post-Emergency Department between June 2022 and March 2024.

The study aims to assess changes in suicidal ideation and behaviour at multiple time points—7 days, 1 month, and 3 months post-treatment—using the Columbia-Suicide Severity Rating Scale (C-SSRS). Secondary outcomes include evaluating depressive symptoms through the Montgomery-Åsberg Depression Rating Scale (MADRS) and tracking hospitalisations or emergency visits related to suicidal ideation.

Topic Suicidality Depression
Compound Ketamine
Country France
Visit trial

Trial Details



Trial Number

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.